ASCO 2022: Sequencing of kidney cancer medicines
During the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Sequencing of treatments for advanced/metastatic kidney cancer
During the American Society of Clinical Oncology Annual Meeting earlier [...]
Does the size of response to cabozantinib plus nivolumab affect clinical outcomes?
Ongoing results from the phase 3 CheckMate-9ER clinical trial with [...]
Can durvalumab or savolitinib alone or in combination with tremelimumab improve survival in patients with metastatic kidney cancer?
At the American Society of Clinical Oncology (ASCO) Annual Meeting [...]
Telaglenastat plus everolimus in advanced kidney cancer
This phase 2 clinical trial (ENTRATA) looked at how safe [...]
Quality of life on lenvatinib plus pembrolizumab combination
In this study, the health-related quality of life (HRQoL) of [...]
MEDI0680 plus durvalumab compared to nivolumab in patients with advanced kidney cancer
MEDI0680 and durvalumab are both immunotherapies called checkpoint inhibitors. They [...]
Kidney cancer patient summit on immunotherapy/TKI combinations
The following presentations from the Educated Patient® Kidney Cancer Summit [...]
EIKCS 2022: Debate about later-line treatments
At the 2022 European International Kidney Cancer Symposium (EIKCS) in [...]
EIKCS 2022: Which is the best combination therapy?
During 2022 European International Kidney Cancer Symposium (EIKCS) in Antwerp, [...]
